Macrocyclic heterocyclic aspartyl protease inhibitors
    2.
    发明授权
    Macrocyclic heterocyclic aspartyl protease inhibitors 有权
    大环杂环天门冬酰胺蛋白酶抑制剂

    公开(公告)号:US08557798B2

    公开(公告)日:2013-10-15

    申请号:US12620291

    申请日:2009-11-17

    IPC分类号: A61K31/33 C07D245/00

    CPC分类号: C07D487/08

    摘要: Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt, solvate or ester thereof, wherein U, W, X, L, Y, M, Z, c, d, e, f, g, h, s, t, R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and R18 are as defined in the specification; and pharmaceutical compositions comprising the compounds of formula I. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.

    摘要翻译: 公开了式I化合物或其立体异构体,互变异构体或其药学上可接受的盐,溶剂化物或酯,其中U,W,X,L,Y,M,Z,c,d,e,f,g, s,t,R1,R2,R7,R8,R9,R10,R11,R12,R13,R14,R15,R16,R17和R18如说明书中所定义; 以及包含式I化合物的药物组合物。还公开了抑制天冬氨酰蛋白酶的方法,特别是治疗心血管疾病,认知和神经变性疾病的方法。 还公开了使用式I化合物与胆碱酯酶抑制剂或毒蕈碱m1激动剂或m2拮抗剂组合治疗认知或神经变性疾病的方法。

    Macrocyclic tetrazolyl hepatitis C serine protease inhibitors
    3.
    发明授权
    Macrocyclic tetrazolyl hepatitis C serine protease inhibitors 有权
    大环四唑丙型肝炎丝氨酸蛋白酶抑制剂

    公开(公告)号:US08304385B2

    公开(公告)日:2012-11-06

    申请号:US12270963

    申请日:2008-11-14

    摘要: The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

    摘要翻译: 本发明涉及式I,II,III或IV化合物或其药学上可接受的盐,酯或前药:其抑制丝氨酸蛋白酶活性,特别是丙型肝炎病毒(HCV)NS3-NS4A蛋白酶的活性。 因此,本发明的化合物干扰丙型肝炎病毒的生命周期,也可用作抗病毒剂。 本发明还涉及药物组合物,其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Responsive luminescent lanthanide complexes
    5.
    发明授权
    Responsive luminescent lanthanide complexes 有权
    响应性发光镧系元素络合物

    公开(公告)号:US08193174B2

    公开(公告)日:2012-06-05

    申请号:US11913991

    申请日:2006-05-11

    CPC分类号: C07D495/04

    摘要: The invention provides a compound comprising a xanthone or thiaxanthone sensitizing moiety, capable of coordinating to a lanthanide ion by the nitrogen atom of an integral pyridyl group or a related group able to bind a lanthanide ion.

    摘要翻译: 本发明提供一种包含呫吨酮或噻吩酮敏化部分的化合物,其能够通过整体吡啶基的氮原子或能够结合镧系元素离子的相关基团与镧系元素离子配位。